The framework the new FDA leaders laid out on Tuesday raised small and big questions about the regulatory process, vaccine access, and medical ethics.

A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make a broad recommendation about which lineage of the coronavirus should be included in this year’s Covid-19 vaccines,

The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the virus, and those older than age 65.

Peter A. McCullough, a former cardiologist who promoted unproven treatments like ivermectin and hydroxychloroquine at the height of the pandemic, posted a video to Instagram claiming that Biden’s cancer was “turbo cancer.”

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

Despite available vaccines and treatments, COVID-19 continues to cause an average of 350 deaths weekly in the U.S., according to the CDC. Low vaccination rates, waning immunity, and delayed treatment contribute to these ongoing fatalities.

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared to other strains on the rise, but it does have a greater ability to bind to human cells, suggesting it could be more transmissible.